Article Text

See original article:

other Versions

Voriconazole plasma monitoring
  1. Alessandro C Pasqualotto (acpasqualotto{at}
  1. The University of Manchester, United Kingdom
    1. Mamta Shah (mamta.shah{at}
    1. Burn Unit, Booth Hall Children's Hospital, Manchester, United Kingdom
      1. Robert Wynn (robert.wynn{at}
      1. Department of Haematology, Royal Manchester Children's Hospital, Pendlebury, Manchester, United Kingdom
        1. David W Denning (ddenning{at}
        1. The University of Manchester, United Kingdom


          Aims: Very little information is available regarding the use of voriconazole drug monitoring in children with invasive fungal infections. The purpose of this study was to report the cases of 5 paediatric patients treated with voriconazole, in which plasma levels were used to monitor therapy.

          Methods: Five children treated with voriconazole were included in this case series. Voriconazole plasma levels were determined using either bioassay or liquid chromatography-tandem mass spectrometry.

          Results: The patients' ages ranged from 2-10 years-old (mean 6.2 years-old). Three patients had acute leukaemia and 2 suffered severe burn injuries. Doses administered varied from 3.4 mg/kg every 12 hours to 8.1 mg/kg every 8 hours. Plasma voriconazole concentrations were unpredictable for these paediatric patients. Subtherapeutic levels were frequently observed, despite progressive increments in dosage. For others, voriconazole levels markedly increased after a small increment in dosage. Phenobarbitone caused important drug interactions with voriconazole for 2 of the patients.

          Conclusions: Dose administered did not correlate with exposure as measured by plasma levels of voriconazole. Whilst the optimal dosage for voriconazole in children is still unknown, drug monitoring seems warranted to ensure adequate exposure, and after dose increments to prevent excessive exposure. Drug interactions significantly altered exposure.

          • antifungal drugs
          • aspergillosis
          • children
          • drug monitoring
          • voriconazole

          Statistics from

          Review history and Supplementary material

          • erratum 93/7/578

            Erratum from the authors

            We mention in the abstract that 'Phenobarbitone caused important drug interactions with voriconazole for 2 of the patients'. Actually that occurred for only one patient, so the correct sentence would be 'Phenobarbitone caused important drug interactions with voriconazole for one of the patients'.

            Request Permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

            Linked Articles

            • Correction
              BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health